Fig. 1From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinomaFlow chart shows the screening procedure for recurrent HCC patients with treated with TACE-camrelizumab or TACE-alone. HCC = hepatocellular carcinoma, R-HCC = recurrent hepatocellular carcinoma, TACE = transarterial chemoembolization, TAI = transcatheter arterial infusion, RFA = radiofrequency ablationBack to article page